

1 **TITLE**

2 SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over
3 time likely through serial Founder Events and mutational bursts.

4

5 **AUTHORS**

6 Rafail Nikolaos Tasakis^{1,2}, Georgios Samaras^{1,3}, Anna Jamison^{4¶}, Michelle Lee^{5¶}, Alexandra
7 Paulus^{4¶}, Gabrielle Whitehouse^{4¶}, Laurent Verkoczy^{6*}, F. Nina Papavasiliou^{1*} and Marilyn
8 Diaz^{6*}

9

10 **AFFILIATIONS**

11 ¹Division of Immune Diversity, German Cancer Research Center (DKFZ), Heidelberg,
12 Germany.

13 ²Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.

14 ³Program of Translational Medical Research, Medical Faculty Mannheim, University of
15 Heidelberg, Germany

16 ⁴The Nightingale-Bamford School, New York, NY, USA

17 ⁵Cornell University, Ithaca, NY, USA

18 ⁶San Diego Biomedical Research Institute (SDBRI), San Diego, CA, USA

19

20

21 ¶ These authors contributed equally to this work.

22 * Co-corresponding authors

23 Email: mdiaz@SDBRI.ORG (MD)

24 Email: lverkoczy@SDBRI.ORG (LV)

25 Email: n.papavasiliou@dkfz-heidelberg.de (FNP)

26

27

28

29 **ABSTRACT**

30 Since the first case of COVID-19 in December 2019 in Wuhan, China, SARS-CoV-2
31 has spread worldwide and within a year has caused 2.29 million deaths globally. With
32 dramatically increasing infection numbers, and the arrival of new variants with increased
33 infectivity, tracking the evolution of its genome is crucial for effectively controlling the pandemic
34 and informing vaccine platform development. Our study explores evolution of SARS-CoV-2 in
35 a representative cohort of sequences covering the entire genome in the United States, through
36 all of 2020 and early 2021. Strikingly, we detected many accumulating Single Nucleotide
37 Variations (SNVs) encoding amino acid changes in the SARS-CoV-2 genome, with a pattern
38 indicative of RNA editing enzymes as major mutators of SARS-CoV-2 genomes. We report
39 three major variants through October of 2020. These revealed 14 key mutations that were
40 found in various combinations among 14 distinct predominant signatures. These signatures
41 likely represent evolutionary lineages of SARS-CoV-2 in the U.S. and reveal clues to its
42 evolution such as a mutational burst in the summer of 2020 likely leading to a homegrown new
43 variant, and a trend towards higher mutational load among viral isolates, but with occasional
44 mutation loss. The last quartile of 2020 revealed a concerning accumulation of mostly novel
45 low frequency replacement mutations in the Spike protein, and a hypermutable glutamine
46 residue near the putative furin cleavage site. Finally, the end of the year data revealed the
47 presence of known variants of concern including B.1.1.7, which has acquired additional Spike
48 mutations. Overall, our results suggest that predominant viral sequences are dynamically
49 evolving over time, with periods of mutational bursts and unabated mutation accumulation.
50 This high level of existing variation, even at low frequencies and especially in the Spike-
51 encoding region may become problematic when superspreader events, akin to serial
52 Founder Events in evolution, drive these rare mutations to prominence.

53

54

55

56

57 **AUTHOR SUMMARY**

58 The pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute
59 respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused the death of more than 2.29
60 million people and continues to be a severe threat internationally. Although simple measures
61 such as social distancing, periodic lockdowns and hygiene protocols were immediately put into
62 force, the infection rates were only temporarily minimized. When infection rates exploded again
63 new variants of the virus began to emerge. Our study focuses on a representative set of
64 sequences from the United States throughout 2020 and early 2021. We show that the driving
65 force behind the variants of public health concern, is widespread infection and superspread
66 events. In particular, we show accumulation of mutations over time with little loss from genetic
67 drift, including in the Spike region, which could be problematic for vaccines and therapies. This
68 lurking accumulated genetic variation may be a superspread event from becoming more
69 common and lead to variants that can escape the immune protection provided by the existing
70 vaccines.

71

72 **INTRODUCTION**

73 The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes
74 the Coronavirus disease 2019 (COVID-19), was first detected in December 2019 in Wuhan,
75 China, when a number of severe pneumonia cases were reported [1]. By March 11th, 2020,
76 the COVID-19 outbreak was classified as a pandemic by the World Health Organization (WHO)
77 [2] and as of early February 2021, more than 105 million COVID-19 cases have been confirmed
78 worldwide, while 2.29 million related deaths have been reported [3].

79 SARS-CoV-2 is an enveloped, single-stranded, positive-sense RNA virus and a
80 member of the *betacoronavirus* genera, of the *Coronaviridae* family [4]. The viral envelope of
81 SARS-CoV-2 consists of the membrane (M), envelope (E), nucleocapsid (N) and spike (S)
82 proteins (encoded by the ORF5, ORF4 and ORF2 respectively), crucial components of the
83 viral structure, but also necessary for the packaging of the viral RNA genome, and for viral
84 infectivity [5]. The S protein (also known as Spike glycoprotein), is a major contributor to

85 COVID-19's pathogenesis and tropism, as it is responsible for SARS-CoV-2's recognition,
86 fusion and entrance into host cells. The infection process initiates when the Receptor Binding
87 Domain (RBD; S1 subunit) of the S protein recognizes and binds the angiotensin-converting
88 enzyme 2 (ACE2) receptor of the host, leading to fusion of the viral envelope with the cellular
89 membrane thanks to a hydrophobic fusion peptide sequence found in the S2 subunit of Spike
90 [6].

91 Entrance and subsequent release of the positive strand viral RNA genome in the host
92 cell, is followed directly by its translation into a variety of structural and non-structural proteins
93 crucial for the viral life cycle [7,8]. ORF1a and 1b are the first to be translated and encode the
94 polyproteins pp1a and pp1b, which are cleaved by the papain-like protease (PL^{pro}) and the
95 chymotrypsin-like protease (also referred to as 3C-like protease; 3CL^{pro}) [9]. This results in the
96 production of 16 non-structural proteins (nsp1-11 from pp1a and nsp12-16 from pp1b) [9].
97 Together, these nsps are necessary for the viral life cycle as they regulate the assembly or are
98 components of the Replication-Transcription Complex (RTC) [10]. Nsp1 "hijacks" the
99 translational machinery of the host to prioritize viral protein expression [11], while Nsp2
100 modulates the host's cell cycle progression, migration, differentiation, apoptosis, and
101 mitochondrial biogenesis [12]. Nsp4 interacts with nsp3 and other host proteins to facilitate
102 viral replication [5,12], while the nsp6 protein induces membrane vesicles [13]. Nsp12 functions
103 as an RNA-directed RNA polymerase (RdRp) and synthesizes the viral RNA with the help of
104 the cofactors nsp7 and nsp8 [14]. Nsp14 is also part of the RTC by virtue of its function as a
105 3'-5' exoribonuclease proofreader, among other functions [15]. Additional RTC nsp proteins
106 are nsp9 (capable of binding to RNA), nsp10 (cofactor of nsp14 and nsp16), nsp13 (helicase
107 and 5' triphosphatase), nsp15 (with N7-methyltransferase function) and nsp16 (with 2'-O-
108 methyltransferase function) [5,16]. Once the RTC complex is established, it produces copies
109 of negative-sense viral RNA, which are then used as templates for synthesis of the positive-
110 sense genomic RNA (through an obligatory double stranded RNA intermediate [17]). These
111 new copies of genomic RNA are either translated for the expression of new nonstructural
112 proteins or are assembled into virions toward viral release [5]. Finally, the N protein binds to

113 the newly synthesized positive-sense genomic RNA in the cytoplasm, forming the
114 ribonucleocapsid, which along with the M, S and E proteins, are transported to the endoplasmic
115 reticulum-Golgi intermediate compartment (ERGIC) for virion assembly. The virions exit the
116 Golgi via budding and are released out of the cell through exocytosis [8].

117 All these ORFs encode components crucial to the SARS-CoV-2 life cycle. Genomic
118 variants that alter the amino acid composition of any of these ORFs are of interest. Normally
119 such variants would arise from polymerase-induced mutations during viral replication.
120 However, SARS-CoV-2 (with a genome of ~30 kb) appears to mutate less frequently than
121 viruses with smaller genomes [18], a feature attributed to nsp14, which possesses 3'-5'
122 exoribonuclease proofreading function that repairs some of the RdRp generated errors [15].
123 Indeed, the majority of single nucleotide variants detected in viral genomes (65% of
124 documented mutations [19,20]) are C-to-U and A-to-G base changes, a likely result of the
125 action of RNA editing deaminases [21]. These enzymes of the APOBEC (Apolipoprotein B
126 mRNA editing enzyme, catalytic polypeptide-like) and ADAR (Adenosine Deaminase Acting
127 on RNA) families are normally referred to as anti-viral [22-24]. They target C's in single
128 stranded RNA (as is documented for APOBEC1 [25], APOBEC3A [26,27] and possibly
129 APOBEC3G [28]) or A's in double stranded RNA (generated during viral genome replication–
130 a perfect substrate for ADAR enzymes) to generate transition mutations (C-to-U and A-to-I,
131 decoded as G) [23]. While RNA deamination in general (also referred to as RNA editing) is
132 normally thought of as anti-viral, there is no reason why it cannot power viral evolution as well,
133 and in fact, current data suggest it does so in SARS-CoV-2. Aside from single nucleotide
134 substitutions, there is experimental evidence that, at least *in vitro*, this and earlier
135 coronaviruses (e.g. SARS-1) are capable of recombination, through template strand switching
136 [29].

137 Here, we have tracked the appearance of mutations in the SARS-CoV-2 genome
138 through the first 12 months of the pandemic in the United States. Starting from aggregate
139 mutational profiles, we derived a number of mutational signatures, representing distinct
140 variants, which we have then tracked as they emerged across the U.S. in the course of the

141 pandemic over time. We report an increase of variant emergence and mutations per variant
142 with time, underscoring the need for continued mitigation even in the context of a successful
143 vaccination strategy. Finally, a few of the variants we identify from early 2021 are evolved
144 versions of the British variant of concern (B1.1.7) further underscoring the urgency of a dual
145 strategy of mitigation and vaccination.

146

147 RESULTS

148 **SNVs accumulate progressively with time throughout the SARS-CoV-2 genome.**

149 The SARS-CoV-2 isolates analyzed in this study come from infected American
150 individuals collected between January 19th 2020 and January 6th 2021 and encompass 8171
151 sequences. The number of sequences and locations where they are obtained from are shown
152 in Fig S1. Although viral isolate numbers decrease right after the first wave, a second increase
153 in daily isolate numbers starts from late July onwards. The number of SNVs per viral isolate
154 increases progressively over time (Fig 1A), indicating the virus is not keeping a static genomic
155 profile during the course of the pandemic and is instead accumulating diversity.

156 The kinds of substitutions that characterize the aggregate viral SNV profile are
157 predominantly C>T changes, with A>G, G>T and T>C also abundantly represented (Fig 1B)
158 among all mutations. When examining the mutation pattern among unique (non-ancestral)
159 synonymous changes in an effort to better understand the mechanism generating variability in
160 SARS-CoV-2, we found that C to T (U) and T (U) to C transitions are over-represented among
161 synonymous changes (Table 1; synonymous changes typically roughly represent 1/3 of the
162 mutations). The large number of C to U mutations (by far the most common mutation when
163 only unique mutations are considered) regardless of whether they generate a replacement or
164 not, combined with their excess representation among synonymous changes, suggest the
165 intrinsic signature of the mechanism generating mutations in SARS-CoV-2 involves the
166 generation of C to T mutations with a secondary smaller bias for T to C. These base
167 substitution patterns add to the increasing chorus in the literature that the APOBEC family of
168 RNA editing enzymes may be contributing to SARS-CoV-2 diversity (not entirely surprising

169 considering their known roles in antiviral activity [20,21,24]). In certain ORFs, C to T changes
170 were predominant (Fig 1C) while others deviated from the intrinsic mutational signature such
171 as ORF2 encoding spike, suggesting the intrinsic pattern may be masked by positive selection
172 for other mutations in ORF2.

173 **Table 1.** Nucleotide substitution ratios of synonymous to non-synonymous changes among
174 transistitions, G-to-A, A-to-G, C-to-U, U-to-C.

	G-to-A	A-to-G	C-to-U	U-to-C
Silent (S)	33	52	405	96
Missense (M)	81	81	383	32
Ratio (S/M)	0.41	0.64	1.06	3.0

175
176 In our viral isolate cohort, fourteen specific missense mutations were found at high
177 frequencies in the aggregate sequence data (Fig 2A; Table 2) suggesting they were under
178 positive selection. Mutations that appear in more than 10% of the retrieved sequences whose
179 frequency over time profile suggest at least three major variants include following:

180 (1) in ORF1a, a Threonine-to-Isoleucine (T>I; T265I) change is present at about 48.79%
181 of the sequences leading to a recoding effect in the Nsp2 protein (also found in [30]),
182 which is one of the first viral encoded proteins to initiate the viral life cycle, as well as a
183 Leucine-to-Phenylalanine (L>F; L3352F) in 12.98% of sequences, recoding the
184 peptidase C30. The frequency of this mutation follows a specific pattern (pattern A. Fig
185 2B), where it has overall increased over time concurrently with other mutations of the
186 same pattern as mentioned below.

187 (2) In ORF1b, a Proline-to-Leucine (P>L; P4715L in 82.03% of sequences) appears to be
188 the most frequent mutation found in our cohort and has been previously also found in
189 [31]. In the same ORF, Y5865C (Y>C) and P5828L (P>L) represent recoding changes
190 affecting the DNA/RNA helicase domain, and N6054D and R7014C represent amino
191 acid changes in Nsp14 and Nsp16 respectively [32]. Not all of these mutations follow
192 the same frequency patterns (for example P4715L, P5828L and Y5865C, and R7014C
193 follow distinct patterns (Figure 2B)).

194 (3) In ORF2 an Aspartic-acid-to-Glycine (D614G) change (in 80.76% of sequences),
195 (pattern B, Figure 2B), maps between the receptor-binding domain (RBD) and the S2
196 subunit of the spike. This change has been extensively noted in the literature as a
197 variant associated with an increase in infectivity and appears to have originated in
198 Europe [33].

199 (4) In ORF3a, a Glutamine-to-Histidine (Q>H; Q57H) mutation (~57.62% of the sequences
200 - pattern B, Figure 2B) is also found along with a G172V (G>V) change [34] (pattern A,
201 Figure 2B), both recoding the viroporin protein of SARS-CoV-2 [35].

202 (5) Mutations in the Ig-like (ORF8) and Nucleocapsid (ORF9) proteins of SARS-CoV-2
203 have also been abundantly found: in the first an S24L, which follows a unique frequency
204 pattern (pattern D, Figure 2B), and an L84S change (pattern A, Figure 2B), both at
205 about 15% frequency) [36] and in the latter a P199L change [37] and a P67S alteration,
206 which has not been previously documented, at about 10% of the sequences (with a
207 frequency pattern A – Figure 2B).

208 **Table 2.** Summary of predominant mutations detected in SARS-CoV-2 genomes. Summary
209 information includes: nucleotide change in position vs. the reference genome, ORF and protein
210 amino acid change, related protein and function that the recoding effect may affect and the
211 percentage frequency (% number of sequences found in). The genomic variants presented in
212 this table are the ones found in more than 10% of the sequences and annotated in figure 2A.

Change (Nucleotide)	ORF	Change (Protein)	Protein Function	%Frequency
C14408T	1b	P4715L	Nsp8 interaction site	82.03%
A23403G	2 (S)	D614G	Spike protein; between the RBD and S2 domains	80.76%
G25563T	3a	Q57H	APA3 viroporin – accessory protein	57.62%
C1059T	1a	T265I	Nsp2	48.79%
C27964T	8	S24L	Ig-like protein	15.22%

T28144C	8	L84S	Ig-like protein	14.07%
C10319T	1a	L3352F	Peptidase C30	12.98%
A17858G	1b	Y5865C	DNA/RNA helicase domain	12.34%
C17747T	1b	P5828L	DNA/RNA helicase domain	12.19%
A18424G	1b	N6054D	Nsp14; 3'-5' exonuclease	11.08%
C21304T	1b	R7014C	Nsp16	10.93%
C28472T	9	P67S	Nucleocapsid	10.78%
G25907T	3a	G172V	Viroporin	10.76%
C28869T	9	P199L	Nucleocapsid	10.53%

213

214 The identified patterns of specific mutation groups with near identical “frequency over time”
215 profiles suggest at least three major variants were present in the United States at various time
216 points in 2020. Some of the mutations are found more frequently earlier in the pandemic rather
217 than later (pattern C; Fig 2B) which correlate with the original Wuhan strain and its early
218 derivatives.

219

220 **Mutational signatures over the SARS-CoV-2 genome suggest a combination of genetic**
221 **drift and selection**

222 From our sequence cohort, we determined all potentially distinct mutation combinations
223 among sequences to get a sense of the evolution of SARS-CoV-2 in the United States. We
224 found 48 distinct putative signatures (s0-s48) that ranged from extremely rare (1 genome) to
225 frequent (in more than 10% of the genomes) (Fig S2A). We focused on those signatures that
226 were present in more than 0.1% of the genomes (Fig 2C). Their prevalence as a function of
227 time was also evaluated (Fig 2C, S2B). Three major variants appear to have dominated the
228 landscape in the US in 2020. These include (a) the reference Wuhan sequence which
229 disappeared as of June 2020, (b) the D to G clade (D614G) and various lower frequency but
230 highly similar subvariants and (c) a group of signatures from that clade that appear to have

231 acquired multiple mutations as a burst event in the summer of 2020 (involving at least 5
232 missense mutations (Fig 2C)).

233 These signatures provide enough resolution to examine their distribution across states
234 through time. We focused on states from where sequences were reported both early in the
235 pandemic but also throughout the year. As is clear from Figure 3, significant divergence from
236 the original Wuhan strain is already apparent in mutational profiles of SARS-CoV-2 genomes
237 collected between March and May 2020 (part of the 1st wave). Several mutational signatures
238 become dominant over time and this pattern is specific to some states and seemed to be
239 anchored by the well-known D614G mutation. For example, in California, a diverse set of
240 signatures is present early on, but by the end of 2020, s6, s11, s22, s28 and s48 dominate.
241 Additionally, some signatures are also state-specific such as s41 in MA, and s42 in WI, both
242 very similar to the now ubiquitous s48 but that with the apparent loss of a single mutation in
243 that lineage (Fig 2C), likely through genetic drift. The net effect has been that sequence
244 diversity among viral isolates has increased with time but that diversity may come in bursts as
245 the one seen in the summer of 2020 leading to the s48 signature, likely a homegrown variant
246 (Fig 2C, 3). Intriguingly, one of the mutations that define s48, N6054D, appears to impact the
247 proofreading activity of SARS-CoV-2 [32], raising the possibility that the mutational burst may
248 also be associated with this mutation. These data clearly indicate the genome of SARS-CoV-
249 2 is not static and can adapt through mutation.

250

251 **Appearance of SARS-CoV-2 variants of concern in the U.S.**

252 The functional consequences of variant evolution are most obvious in the context of
253 Spike protein, as mutations in Spike could impact receptor recognition and infectivity (as well
254 as alter antibody binding and thus lead to immune evasion). Therefore, Spike variants are now
255 denoted as “variants of concern”. One of the first variants of concern was the D614G mutation
256 (clade G) [33], which is now found in the vast majority of SARS-CoV-2 genomes (including all
257 genomes recently annotated as novel variants of concern, such as B.1.1.7). Indeed, D614G is
258 present in more than 80% of the sequences in our cohort in aggregate (Fig2A, Table 2), and

259 virtually all sequences from after the 2nd quartile of 2020 (Q2) have this mutation. In addition
260 to the previously described mutations of concern, we have detected 13 isolates with a H69/V70
261 deletion. Of these only three have an additional deletion at V143/Y144 (and additional
262 characteristic mutations which define them as B.1.1.7 lineage (Fig 4A-B) according to [38]. The
263 rest carry the H69/V70 deletion together with a handful of other mutations, matching the
264 B.1.375 lineage (Fig 4B). These 13 isolates, detected in the US after mid-November 2020 both
265 in East and West coasts, have continued to evolve. For example, a B.1.1.7 isolate in Florida
266 carries an additional K1191N mutation, and B.1.375 isolates with additional V578L and
267 C1236S mutations have been sequenced from Florida and California respectively. The
268 K1191N mutation in the HR2 domain of B.1.1.7 has been found in at least one other variant in
269 Bangladesh, suggesting this may be another problematic recurrent mutation under positive
270 selection [39]. These findings highlight the ongoing diversification of the Spike region.

271

272 **Multiple low frequency missense mutations of unknown consequence are accumulating
273 in the region encoding the Spike protein that may warrant close surveillance.**

274 Additional mutations were found in Spike region that are currently at very low
275 frequencies but present in at least 0.1% of sequences (a cutoff selected to minimize
276 sequencing error contribution to the analysis). The consequences of these mutations to
277 infectivity, severity of disease, or response to vaccination remain unknown. They include: L5F
278 (163 genomes), E780Q (83 genomes), P681H (74 genomes) and Q677H (68 genomes; see
279 below), and over 20 additional mostly unidentified amino acid replacing mutations (as
280 summarized in Fig 4C). None of these Spike mutations have been identified as problematic to
281 date, but they remain within the population at very low frequencies. Strikingly, these low
282 frequency spike mutations seem to be increasing over time as more and more mutations
283 accumulate in the 4th quartile - while only a couple have been lost likely from genetic drift (Fig
284 4C). We found that of these low frequency mutations, six are in the receptor binding domain
285 (RBD) (Fig. 4C) and include (with number of genomes in parentheses): V382L (35), L452R
286 (28), F490S (9), S494P (30), N501T (12), and A520S (11), which may have consequences for

287 binding affinities to the ACE2 receptor in human cells, infectivity and/or response to vaccines
288 developed to trigger antibody responses to the RBD of earlier strains. Moreover, we identified
289 two different amino acid substitutions at Q677: Q677R (A23592G) and Q677H (through two
290 different point mutations -G23593T and G23593C) which are very close to the furin cleavage
291 domain. This hypermutability at Q677 suggests that it is under strong selection. A series of low
292 frequency mostly novel mutations in Spike were detected and included (with number of
293 genomes in parentheses): I210V (9) T719S (9), E781Q (32), T860I (10), V1041F (13), V1176F
294 (10), and E1203Q (10). The entire list of low frequency mutations in Spike are shown in Fig.
295 4C. Finally, it is important to note that this low frequency variation in Spike currently present
296 within the US population, may be potentially one superspread event away from prominence,
297 and could lead to problematic new mutations or variants.

298

299 **DISCUSSION**

300 Among positive strand RNA viruses, the genome of SARS-CoV-2 has been thought to
301 be remarkably stable – in part because it has proofreading functionality during RNA synthesis
302 - a function carried out by nsp14 [15]. However, this notion of stability has come under scrutiny
303 with the emergence of multiple variants, some threatening the effectiveness of vaccines, and
304 many coinciding in convergently acquired spike mutations [40]. Indeed, though lacking the
305 diversity seen in HIV-1 variants [41], SARS-CoV-2 is fully capable of acquiring mutations that
306 enhance its ability to spread and evade immune responses.

307 In this study, we aimed to examine SARS-CoV-2 variants in the United States during
308 the first year of the pandemic. We were interested in sampling the existing variation, how
309 variant frequency changes over time and across states and finally, in the potential identification
310 of either new variants or novel mutations in pre-existing variants that have arrived from other
311 parts of the world. We also examined whether the pattern of mutations, particularly among
312 synonymous sites, could provide a clue as to how, despite its proofreading exoribonuclease
313 activity, SARS-CoV-2 has accumulated significant genetic variation.

314 For this study, we obtained 8171 full length sequences from Covid19 patients from
315 January 2020 through January 2021 from 42 US states. It is important to note that a majority
316 of the data was obtained from a handful of states (California, Florida, New York, Maryland,
317 Massachusetts, Minnesota, Virginia, Wisconsin, and Washington (Fig S1B)), likely a
318 combination of available genome surveillance programs, and rates of infection in those states.
319 We identified several distinct variants (Fig 2C, S2A) that can be categorized as follows: **1**) The
320 original Wuhan strain and a few descendants with minor changes. This strain lacks the D614G
321 change that emerged in Europe early in the pandemic (G-clade). The reference strain and its
322 minor subvariants appear to have been lost in most states by early to mid-summer (Fig. 3); **2**)
323 Two versions of the G-clade European strain defined by the acquisition, in an intermediate
324 within the clade, of multiple mutations within a short period of time in the summer of 2020,
325 leading to the now predominant likely homegrown variant s48 signature (Fig 2C). Our analysis
326 is not compatible with the notion that the burst of mutations originated from a recombination
327 event; rather these mutations appear instead to arise from the acquisition of multiple single
328 base substitutions that increased in frequency in the population relatively quickly, likely through
329 serial Founder Events. However, a few examples of lone mutations shared across variants
330 suggest the possibility of recombination or convergent evolution. Bursts of mutations may also
331 originate from patients with persistent infection despite treatment with convalescent plasma
332 where pressure for immune escape variants may be prolonged and intense [42,43].

333 Strikingly, the main variants in the US accumulated an increasing number of mutations
334 over time (Fig 1A, 2B-C, 3, S2B). This underscores the fact that with uncontrolled infection,
335 the appearance of new mutations will increase – and this will augment the probability of the
336 emergence of variants that alter the efficacy of vaccines or other therapeutics (e.g. monoclonal
337 antibodies). Of particular concern is our finding that over the last year in the United States,
338 over 20 amino acid replacing mutations arose in the Spike protein that have not been identified
339 yet as problematic, many still remaining in the population but currently at low frequencies (less
340 than 1%, Fig. 4C). Typically, mutations need to reach non-trivial frequency levels to survive
341 genetic drift and loss from the population. However, the number of amino acid replacements

342 impacting ORF2 encoding Spike seems to be increasing over time, with little corresponding
343 loss of variation through drift (Fig. 4C). This low frequency variation in Spike is of concern
344 because of the number of superspread events in the US population leading to serial Founder
345 Events that can increase the frequency of these rare mutations. Variation reaching non-trivial
346 frequencies through superspread events can then be subjected to positive selection in viral
347 evolution which can come in the form of host immune escape variants: such as arising in
348 immunocompromised patients receiving convalescent plasma [42,43], or in inadequately
349 vaccinated individuals (e.g. having only received a single dose of a two-dose vaccine
350 regimen), or by outperforming other variants through easier spreading for example. The latter
351 may be the reason the D614G variant became the dominant form in most countries [44,45].

352 Superspread events may effectively work as Founder Events in this pandemic. In
353 Founder Events, where a few organisms initiate a new population, typically most genetic
354 variation is lost [46]. However, multiple or serial Founder Events originating from a population
355 can potentiate the generation of new species (or variants in this case) by providing a
356 mechanism for rare mutations to quickly increase their frequency [47]. Therefore, in
357 considering the generation of diversity of SARS-CoV-2, superspreading events is another
358 mechanism, besides mutation, where the virus can effectively increase its diversity over the
359 population. Given this, it is a reasonable possibility that current low frequency Spike mutations
360 may develop into problematic variants through superspread events. This provides a
361 compelling reason to adhere to strict mitigation controls especially in the context of gatherings
362 with potential to become superspread events. Minimizing such events is likely critical to
363 control the generation of clinically relevant variants.

364 Deservedly, a lot of attention has been given to variations in the ORF encoding spike
365 protein (Orf2), since any immune escape mutants are likely to arise particularly (though not
366 exclusively) within the receptor binding domain of Spike, that interacts with the ACE2 receptor
367 [48]. Among variants in Spike, we detected rare instances of the B 1.1.7 variant (3 cases in
368 November in California and Florida) and 10 of the B1.375 variant, recently identified as having
369 the H69/V70 deletion similar to B 1.1.7 but lacking most of the other distinguishing mutations

370 of B.1.1.7 [49]. This novel lineage (B.1.375) is another example of the H69/V70 deletion been
371 found in independent variants, suggesting it evolved convergently multiple times in SARS-
372 CoV-2 variants (as recognized by others [50]) even among different species [51]. Recent
373 models suggest that the H69/V70 deletion may be a gateway alteration to more variation as it
374 may provide increased flexibility of the receptor binding domain to accommodate mutations in
375 the ACE2 receptor among individuals and/or species [48], but this remains speculative.
376 Specific caution is warranted with genomic surveillance of SARS-CoV-2 genomes containing
377 this deletion (whether it is B1.1.7 or not) as it seems to be associated with the generation of
378 new variants of clinical relevance.

379 In addition to variants within the ORF encoding spike protein (Orf2), we and others
380 found significant variation in other Orfs such as Orf1a and 1b and others, including a 15bp
381 deletion in the region encoding NSP1, previously identified in Japan [52]. The functional
382 relevance of this variation is less clear but cannot be ignored as it may impact the virus ability
383 to replicate, infect other cells once inside the host, and even modulate the host immune
384 response (as has been observed for NSP1 [52]). Therefore, while these non-spike variants
385 may not impact vaccine efficacy, they may impact the severity of the disease and potentially
386 the spread of the virus by increasing its efficiency in hijacking host cells and lowering the viral
387 load threshold required to establish infection.

388 Because the SARS-CoV-2 genome is not as stable as initially thought despite its
389 proofreading activity, we examined the pattern of mutation among synonymous changes
390 throughout the 8171 SARS-CoV-2 genomes to try to establish the intrinsic signatures of the
391 mechanisms that result in SARS-CoV-2 mutations. Querying synonymous mutations, we found
392 that C-to-U and U-to-C transitions were abundant and among all mutations, C-to-U changes
393 were dominant. One source of C-to-U mutations in RNA is the APOBEC family of RNA editing
394 enzymes, some with anti-viral properties known to deliberately attack the genomes or RNA
395 viruses, such as in the case of Apobec3G and HIV [53]. The less frequent U-to-C mutations
396 could also be due to RNA modification events occurring on uracil, and decoded as cytosine;
397 modifications that could result in such a profile could include thiolation (e.g. 4-thio-uridine) or

398 aminocarboxypropylation (e.g. acp3U) events. Though these modifications have not yet been
399 reported to occur on mRNA, both can occur on tRNA [54,55]. Finally, A-to-G events are also
400 evident (and the likely result of adenosine deamination to inosine, decoded as guanosine,
401 which is catalyzed by ADAR proteins, whose preference for dsRNA targets could attract them
402 to double-stranded RNA intermediates of the viral replication process) – for example the
403 prominent G clade mutation (D614G) may be the outcome of an A-to-I deamination event at
404 position A23403).

405 While we are not the first to make the observation that the SARS-CoV-2 genome is a
406 target of modification enzymes [21, 56-58], the fact that (a) many of the mutations that have
407 given rise to variants of concern could be explained by such modification events, together with
408 the fact that (b) modification enzymes have a preference with regard to the nucleotides that
409 neighbor the base-to-be-modified, lead us to speculate that RNA modifications are a major
410 source of targeted mutagenesis of the viral genome. This would explain why emerging variants
411 (like the B1.1.7), rather than diverging in sequence, appear to be acquiring mutations common
412 to unrelated strains (e.g. the new acquisition of the E484K (**GAA=>AAA** mutation first defined
413 as concerning in the unrelated 501Y.V2 variant [59], which could be attributed to a modification
414 such as m1G, which can be decoded as A [60]). Overall, this may be good news, as it would
415 imply that the range of sequence alterations that can yield variants of concern is limited, and
416 can be effectively targeted by novel vaccination strategies. This does not eliminate the
417 potential for recombination as another source of variation, as seen often in coronaviruses [29],
418 however we did not detect evidence of recombination events in the sequences we queried
419 here.

420 A troubling implication of the emergence of Spike variants is the potential for the
421 concurrent development of antibodies that are optimal for the original strains but not for the
422 new strains which may lead to the development of antibody-dependent enhancement (ADE)
423 documented for other viruses and associated with the development of suboptimal antibodies
424 [61]. Fortunately, ADE has not emerged explicitly as a substantial concern with SARS-CoV-2
425 [62,63], although suspects are the MIS-C or MIS-A, the Kawasaki-like syndromes associated

426 with COVID-19 infection and re-infection both in children and more recently also in adults
427 [64,65].

428 From a public health perspective, this study underscores the critical importance of
429 mitigating infection levels and particularly, super-spreader events, as critical potential
430 generators of high frequency novel variants from the very low frequency existing and
431 increasing Spike mutation pool. Indeed, the finding of over 20 spike variants at low frequencies
432 in the population of the U.S., is concerning as this “lurking” genetic variation can quickly
433 emerge as novel variants through superspreader, Founder-like events in an expansion process
434 similar to genetic surfing [66,67]. All these considerations require, in addition to recommended
435 mitigation efforts such as social distancing and mask wearing, that large scale vaccination be
436 in accordance to the schedules used in the clinical trials leading to federal agency approval.
437 Further supporting this, are reports of problematic variants arising within individual
438 immunocompromised patients treated with convalescent sera [42] as these escape mutants
439 can clearly arise when subjected to low levels of anti-Spike protein antibody. This, and our
440 finding of potential “lurking” low frequency variants already within the population, dictate that
441 selection against this virus through vaccination be strong and that “taking the foot off the pedal”
442 (for example by allowing people to have a single dose, or by low second shot compliance) can
443 allow this existing variation to give rise to novel escape variants. This explicitly means that
444 vaccinating more people with a single dose, but delaying the second, could lead to suboptimal
445 protection and therefore mild selection pressure on the circulating variants, allowing for the
446 evolution of more robust escape mutants.

447

448 **METHODS**

449 **The dataset**

450 The NCBI SARS-CoV-2 Resources portal (<https://www.ncbi.nlm.nih.gov/sars-cov-2/>)
451 was the source for all SARS-CoV-2 sequences employed in this study. To fulfill the criteria of
452 nucleotide completeness (complete coverage), 8171 viral isolate sequences were retrieved
453 and isolated from human infections in the USA. Sequences retrieved by the time of analysis

454 were isolated from infections reported between January 19th, 2020 and January 6th, 2021
455 (noted as “Collection Date” in the database). In our analyses we considered the collection date
456 as the most relevant parameter and interpreted our results according to this time frame.

457

458 **Variant calling and annotation**

459 As the reference genome, we considered the one isolated from patient-zero in Wuhan,
460 China (accession number NC_045512 in RefSeq). Alignments were performed with the
461 Multiple Sequence Alignment tool “Clustal Omega” [68,69], comparing each US state
462 separately against the reference genome. We used Clustal alignment outputs (with character
463 counts) as input for our python 3.8 script to call SNVs (Single Nucleotide Variation), which
464 incorporated from ‘biopython’ [70] alignment reading commands for outputs of variation from
465 the reference. Translation of SNVs to note amino acid changes were processed with an R
466 (4.0.2) script, which applied the genetic code on reference sequence to display amino acid
467 variation and thus highlight missense and silent mutations. Annotation of genomic variants with
468 regards to regions in the viral genome (organized into ORFs) was performed employing NCBI
469 RefSeq SARS-CoV-2 genome annotation, which is also publicly available in the NCBI SARS-
470 CoV-2 Resources portal. Most variants and evolutionary signatures called throughout the
471 dataset were visually inspected for validation of SNVs (and presumed amino acid changes).
472 For further analysis and processing different cut-off parameters were followed: as most
473 frequent variants in aggregate (Fig 2A, Table 1) we defined the missense mutations that are
474 present in at least 10% of the sequence cohort (>817 sequences), same cut-off was for the
475 nucleotide changes, but including both silent and missense mutations. For the low frequency
476 Spike mutations, we considered the Spike missense mutations present in more than 0.1% of
477 the sequences.

478 For detecting specific deletions (eg ΔH69/V70) we employed the BLAST (Basic Local
479 Alignment Search Tool) command line application, by calling for gap-containing sequences
480 compared to the reference, in a locally-constructed database with all viral isolate sequences
481 (n=8171) satisfying the aforementioned criteria.

482

483 **Mutational signatures analysis**

484 We defined sequences with distinct combinations of the most frequently detected
485 mutations in SARS-CoV-2 genomes as mutational signatures (Figure 2A; Table 2). All unique
486 combinations were called to build a reference of putative mutational signatures (Fig S2A). We
487 focused on those signatures that were found in more than 0.1% of the sequences (>8). Time-
488 scaled phylogenetic tree of the major signatures (>0.1%) was constructed with IQ-TREE 2
489 [71].

490

491 **Statistical analyses and visualization**

492 All statistical analyses and visualizations were performed in R programming language
493 (v. 4.0.2) employing the R stats package, as well as the Tidyverse (v. 1.3.0) [72], pheatmap (v.
494 1.0.12), dendextent (v. 1.14.0) [73], msa [74], treeio [75] and ggtree [76].

495

496 **AUTHOR CONTRIBUTIONS**

497 This study was conceived by RNT in the summer of 2020 as a summer research project for
498 students from the Nightingale Bamford School, New York. Together with AJ, AP, GW, and ML
499 (a recent alumna), they are responsible for all data collection and analysis. Additional analyses
500 over the fall of 2020 were completed by GS, using the pipelines and scripts established over
501 the summer. MD, LV and FNP provided data interpretation and wrote the manuscript together
502 with GS and RNT.

503

504 **ACKNOWLEDGEMENTS**

505 AJ, AP, GW, and ML would like to acknowledge Dr Naomi Kohen of the Nightingale Bamford
506 School and the school's support for the independent science research program in Heidelberg.

507

508 **CONFLICTS OF INTEREST**

509 The authors declare no conflicts of interest.

510

511 **REFERENCES**

512 1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health
513 concern. *The Lancet*. 2020 Feb 15;395(10223):470–3.

514 2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Bio Medica Atenei
515 Parm*. 2020;91(1):157–60.

516 3. Coronavirus disease (COVID-19) – World Health Organization [Internet]. [cited 2021 Feb
517 9]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

518 4. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication:
519 implications for SARS-CoV-2. *Nat Rev Microbiol*. 2020 Oct 28;1–16.

520 5. Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS
521 CoV-2 or n-COV19), the Cause of COVID-19. *Protein J*. 2020 Jun;39(3):198–216.

522 6. Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, et al. Key residues of the receptor binding motif
523 in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
524 *Cell Mol Immunol*. 2020 Jun;17(6):621–30.

525 7. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into
526 SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural
527 genomics approach. *Biochim Biophys Acta - Mol Basis Dis*. 2020 Oct
528 1;1866(10):165878.

529 8. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and
530 pathogenesis. *J Med Virol*. 2020;92(4):418–23.

531 9. Fang SG, Shen H, Wang J, Tay FPL, Liu DX. Proteolytic processing of polyproteins 1a
532 and 1ab between non-structural proteins 10 and 11/12 of Coronavirus infectious

533 bronchitis virus is dispensable for viral replication in cultured cells. *Virology*. 2008 Sep
534 30;379(2):175–80.

535 10. Slanina H, Madhugiri R, Bylapudi G, Schultheiß K, Karl N, Gulyaeva A, et al. Coronavirus
536 replication–transcription complex: Vital and selective NMPylation of a conserved site in
537 nsp9 by the NiRAN-RdRp subunit. *Proc Natl Acad Sci [Internet]*. 2021 Feb 9 [cited 2021
538 Feb 9];118(6). Available from: <https://www.pnas.org/content/118/6/e2022310118>

539 11. Schubert K, Karousis ED, Jomaa A, Scaiola A, Echeverria B, Gurzeler L-A, et al. SARS-
540 CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. *Nat Struct Mol
541 Biol*. 2020 Oct;27(10):959–66.

542 12. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-
543 2019: The role of the nsp2 and nsp3 in its pathogenesis. *J Med Virol*. 2020;92(6):584–8.

544 13. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et al.
545 Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6)
546 could affect viral autophagy. *J Infect*. 2020 Jul 1;81(1):e24–7.

547 14. Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7
548 and nsp8 co-factors. *Nat Commun*. 2019 May 28;10(1):2342.

549 15. Ogando NS, Zevenhoven-Dobbe JC, Meer Y van der, Bredenbeek PJ, Posthuma CC,
550 Snijder EJ. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for
551 Replication of MERS-CoV and SARS-CoV-2. *J Virol [Internet]*. 2020 Nov 9 [cited 2021
552 Feb 9];94(23). Available from: <https://jvi.asm.org/content/94/23/e01246-20>

553 16. Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y, et al. Structural basis and functional
554 analysis of the SARS coronavirus nsp14–nsp10 complex. *Proc Natl Acad Sci*. 2015 Jul
555 28;112(30):9436–41.

556 17. Klein S, Cortese M, Winter SL, Wachsmuth-Melm M, Neufeldt CJ, Cerikan B, et al.
557 SARS-CoV-2 structure and replication characterized by in situ cryo-electron
558 tomography. *Nat Commun.* 2020 Nov 18;11(1):5885.

559 18. Flaherty P, Natsoulis G, Muralidharan O, Winters M, Buenrostro J, Bell J, et al.
560 Ultrasensitive detection of rare mutations using next-generation targeted resequencing.
561 *Nucleic Acids Res.* 2012 Jan;40(1):e2.

562 19. Wang R, Hozumi Y, Zheng Y-H, Yin C, Wei G-W. Host Immune Response Driving
563 SARS-CoV-2 Evolution. *Viruses* [Internet]. 2020 Sep 27 [cited 2021 Feb 9];12(10).
564 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599751/>

565 20. Klimczak LJ, Randall TA, Saini N, Li J-L, Gordenin DA. Similarity between mutation
566 spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes
567 accumulated during the COVID-19 pandemic. *PLOS ONE.* 2020;15(10):e0237689.

568 21. Giorgio SD, Martignano F, Torcia MG, Mattiuz G, Conticello SG. Evidence for host-
569 dependent RNA editing in the transcriptome of SARS-CoV-2. *Sci Adv.* 2020 Jun
570 1;6(25):eabb5813.

571 22. Liu M-C, Liao W-Y, Buckley KM, Yang SY, Rast JP, Fugmann SD. AID/APOBEC-like
572 cytidine deaminases are ancient innate immune mediators in invertebrates. *Nat
573 Commun.* 2018 May 16;9(1):1948.

574 23. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. *Annu Rev
575 Biochem.* 2010;79:321–49.

576 24. Stavrou S, Ross SR. APOBEC3 Proteins in Viral Immunity. *J Immunol.* 2015 Nov
577 15;195(10):4565–70.

578 25. Rosenberg BR, Hamilton CE, Mwangi MM, Dewell S, Papavasiliou FN. Transcriptome-
579 wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3'
580 UTRs. *Nat Struct Mol Biol.* 2011 Feb;18(2):230–6.

581 26. Sharma S, Patnaik SK, Taggart RT, Kannisto ED, Enriquez SM, Gollnick P, et al.
582 APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages.
583 *Nat Commun.* 2015 Apr 21;6:6881.

584 27. Jalili P, Bowen D, Langenbucher A, Park S, Aguirre K, Corcoran RB, et al. Quantification
585 of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots.
586 *Nat Commun.* 2020 Jun 12;11(1):2971.

587 28. Sharma S, Baysal BE. Stem-loop structure preference for site-specific RNA editing by
588 APOBEC3A and APOBEC3G. *PeerJ.* 2017;5:e4136.

589 29. Gallaher WR. A palindromic RNA sequence as a common breakpoint contributor to copy-
590 choice recombination in SARS-CoV-2. *Arch Virol.* 2020 Oct 1;165(10):2341–8.

591 30. Laha S, Chakraborty J, Das S, Manna SK, Biswas S, Chatterjee R. Characterizations of
592 SARS-CoV-2 mutational profile, spike protein stability and viral transmission. *Infect*
593 *Genet Evol.* 2020 Nov;85:104445.

594 31. Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotani K. SARS-CoV-2 genomic
595 variations associated with mortality rate of COVID-19. *J Hum Genet.* 2020
596 Dec;65(12):1075–82.

597 32. Pater AA, Bosmeny MS, Barkau CL, Ovington KN, Chilamkurthy R, Parasrampuria M, et
598 al. Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United
599 States. *bioRxiv.* 2021 Jan 19;2021.01.11.426287.

600 33. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH, et al. SARS-CoV-2 D614G
601 variant exhibits efficient replication ex vivo and transmission in vivo. *Science*. 2020 Dec
602 18;370(6523):1464–8.

603 34. Hassan SS, Choudhury PP, Uversky VN, Dayhoff GW, Aljabali AAA, Uhal BD, et al.
604 Variability of Accessory Proteins Rules the SARS-CoV-2 Pathogenicity. *bioRxiv*. 2020
605 Nov 8;2020.11.06.372227.

606 35. Issa E, Merhi G, Panossian B, Salloum T, Tokajian S. SARS-CoV-2 and ORF3a:
607 Nonsynonymous Mutations, Functional Domains, and Viral Pathogenesis. *mSystems*
608 [Internet]. 2020 Jun 30 [cited 2021 Feb 9];5(3). Available from:
609 <https://msystems.asm.org/content/5/3/e00266-20>

610 36. Wang R, Chen J, Gao K, Hozumi Y, Yin C, Wei G-W. Characterizing SARS-CoV-2
611 mutations in the United States. *Res Sq* [Internet]. 2020 Aug 11 [cited 2021 Feb 9];
612 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430589/>

613 37. Arévalo SJ, Sifuentes DZ, Robles CH, Bianchi GL, Chávez AC, Casas RG-S, et al.
614 Analysis of the Dynamics and Distribution of SARS-CoV-2 Mutations and its Possible
615 Structural and Functional Implications. *bioRxiv*. 2020 Nov 14;2020.11.13.381228.

616 38. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic
617 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat*
618 *Microbiol*. 2020 Nov;5(11):1403–7.

619 39. Saha O, Shatadru RN, Rakhi NN, Islam I, Hossain MS, Rahaman MM. Temporal
620 landscape of mutation accumulation in SARS-CoV-2 genomes from Bangladesh:
621 possible implications from the ongoing outbreak in Bangladesh. *bioRxiv*. 2020 Aug
622 21;2020.08.20.259721.

623 40. Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern?
624 Lancet Respir Med [Internet]. 2021 Jan 29 [cited 2021 Feb 9];0(0). Available from:
625 [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(21\)00075-8/abstract](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00075-8/abstract)

626 41. Verkoczy L, Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications
627 for their function & induction by vaccination. Curr Opin HIV AIDS. 2014 May;9(3):224–
628 34.

629 42. Kemp SA, Collier DA, Dahir R, Ferreira I, Gayed S, Jahun A, et al. Neutralising antibodies
630 in Spike mediated SARS-CoV-2 adaptation. medRxiv. 2020 Dec
631 29;2020.12.05.20241927.

632 43. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and
633 Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020 Dec
634 3;383(23):2291–3.

635 44. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking
636 Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the
637 COVID-19 Virus. Cell. 2020 Aug 20;182(4):812-827.e19.

638 45. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation
639 D614G alters SARS-CoV-2 fitness. Nature. 2020 Oct 26;1–6.

640 46. Provine WB. Ernst Mayr: Genetics and Speciation. Genetics. 2004 Jul 1;167(3):1041–6.

641 47. Clegg SM, Degnan SM, Kikkawa J, Moritz C, Estoup A, Owens IPF. Genetic
642 consequences of sequential founder events by an island-colonizing bird. Proc Natl Acad
643 Sci. 2002 Jun 11;99(12):8127–32.

644 48. Shah M, Ahmad B, Choi S, Woo HG. Mutations in the SARS-CoV-2 spike RBD are
645 responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-
646 neutralization. Comput Struct Biotechnol J. 2020 Jan 1;18:3402–14.

647 49. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et al.
648 Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–
649 January 12, 2021. *Morb Mortal Wkly Rep.* 2021 Jan 22;70(3):95–9.

650 50. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, et al. Two-step strategy for
651 the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with
652 spike deletion H69-V70, France, August to December 2020. *medRxiv.* 2021 Jan
653 11;2020.11.10.20228528.

654 51. Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger E,
655 Molenkamp R, et al. Transmission of SARS-CoV-2 on mink farms between humans and
656 mink and back to humans. *Science.* 2021 Jan 8;371(6525):172–7.

657 52. Lin J, Tang C, Wei H, Du B, Chen C, Wang M, et al. Genomic monitoring of SARS-CoV-2
658 uncovers an Nsp1 deletion variant that modulates type I interferon response. *Cell Host
659 Microbe.* 2021 Jan;S1931312821000457.

660 53. Wang X, Ao Z, Chen L, Kobinger G, Peng J, Yao X. The Cellular Antiviral Protein
661 APOBEC3G Interacts with HIV-1 Reverse Transcriptase and Inhibits Its Function during
662 Viral Replication. *J Virol.* 2012 Apr 1;86(7):3777–86.

663 54. Edwards AM, Addo MA, Dos Santos PC. Extracurricular Functions of tRNA Modifications
664 in Microorganisms. *Genes.* 2020 Aug;11(8):907.

665 55. Meyer B, Immer C, Kaiser S, Sharma S, Yang J, Watzinger P, et al. Identification of the
666 3-amino-3-carboxypropyl (acp) transferase enzyme responsible for acp3U formation at
667 position 47 in *Escherichia coli* tRNAs. *Nucleic Acids Res.* 2020 Feb 20;48(3):1435–50.

668 56. Miladi M, Fuchs J, Maier W, Weigang S, Pedrosa ND i, Weiss L, et al. The landscape of
669 SARS-CoV-2 RNA modifications. *bioRxiv.* 2020 Jul 18;2020.07.18.204362.

670 57. Poulain F, Lejeune N, Willemart K, Gillet NA. Footprint of the host restriction factors
671 APOBEC3 on the genome of human viruses. *PLOS Pathog.* 2020;16(8):e1008718.

672 58. Simmonds P. Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other
673 Coronaviruses: Causes and Consequences for Their Short- and Long-Term
674 Evolutionary Trajectories. Schwemmle M, editor. *mSphere*. 2020 Jun 24;5(3):e00408-
675 20, /msphere/5/3/mSphere408-20.atom.

676 59. Wise J. Covid-19: The E484K mutation and the risks it poses. *BMJ*. 2021 Feb
677 5;372:n359.

678 60. Werner S, Schmidt L, Marchand V, Kemmer T, Falschlunger C, Sednev MV, et al.
679 Machine learning of reverse transcription signatures of variegated polymerases allows
680 mapping and discrimination of methylated purines in limited transcriptomes. *Nucleic
681 Acids Res.* 2020 Apr 17;48(7):3734–46.

682 61. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-
683 dependent enhancement of severe dengue disease in humans. *Science*. 2017 Nov
684 17;358(6365):929–32.

685 62. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A
686 perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature*.
687 2020 Aug;584(7821):353–63.

688 63. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and
689 SARS-CoV-2 vaccines and therapies. *Nat Microbiol.* 2020 Oct;5(10):1185–91.

690 64. Morris SB. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with
691 SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020.
692 *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 [cited 2021 Feb 12];69. Available from:
693 <https://www.cdc.gov/mmwr/volumes/69/wr/mm6940e1.htm>

694 65. CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) [Internet]. Centers for
695 Disease Control and Prevention. 2020 [cited 2021 Feb 12]. Available from:
696 <https://www.cdc.gov/mis-c/cases/index.html>

697 66. Slatkin M, Excoffier L. Serial Founder Effects During Range Expansion: A Spatial Analog
698 of Genetic Drift. *Genetics*. 2012 May 1;191(1):171–81.

699 67. Travis JMJ, Münkemüller T, Burton OJ, Best A, Dytham C, Johst K. Deleterious
700 Mutations Can Surf to High Densities on the Wave Front of an Expanding Population.
701 *Mol Biol Evol*. 2007 Oct 1;24(10):2334–43.

702 68. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation
703 of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst*
704 *Biol*. 2011 Oct 11;7:539.

705 69. Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein
706 sequences. *Protein Sci Publ Protein Soc*. 2018 Jan;27(1):135–45.

707 70. Biopython: freely available Python tools for computational molecular biology and
708 bioinformatics | Bioinformatics | Oxford Academic [Internet]. [cited 2021 Feb 9].
709 Available from: <https://academic.oup.com/bioinformatics/article/25/11/1422/330687>

710 71. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et
711 al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the
712 Genomic Era. *Mol Biol Evol*. 2020 May 1;37(5):1530–4.

713 72. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to
714 the Tidyverse. *J Open Source Softw*. 2019 Nov 21;4(43):1686.

715 73. Galili T. dendextend: an R package for visualizing, adjusting and comparing trees of
716 hierarchical clustering. *Bioinforma Oxf Engl*. 2015 Nov 15;31(22):3718–20.

717 74. Bodenhofer U, Bonatesta E, Horejš-Kainrath C, Hochreiter S. msa: an R package for
718 multiple sequence alignment. *Bioinformatics*. 2015 Dec 15;31(24):3997–9.

719 75. Wang L-G, Lam TT-Y, Xu S, Dai Z, Zhou L, Feng T, et al. Treeio: An R Package for
720 Phylogenetic Tree Input and Output with Richly Annotated and Associated Data. *Mol
721 Biol Evol*. 2020 Feb 1;37(2):599–603.

722 76. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. ggtree: an r package for visualization and
723 annotation of phylogenetic trees with their covariates and other associated data.
724 *Methods Ecol Evol*. 2017;8(1):28–36.

725

726

727 **FIGURE CAPTIONS AND FIGURES**

728 **Figure 1. SARS-CoV-2 viral genomes accumulate specific sets of SNVs over time. (A)**
729 Frequency histogram showing the steady increase of SNVs called per viral isolate over time
730 (Collection Date), indicating their aggregation in SARS-CoV-2 genomes. **(B)** Distribution of
731 substitutions at unique SNVs. Two of the most frequent SNV substitutions, C>T and A>G, have
732 been previously associated with APOBEC and ADAR deaminase activities, on the SARS-CoV-
733 2 ssRNA(+) genome or its dsRNA intermediate, respectively. **(C)** Graphical representation of
734 SNV substitution profiles at various SARS-CoV-2 ORFs, illustrating intrinsic mutational bias
735 for C>T dominating the mutation pattern in some ORF's (i.e. 1a and 1b), but being masked
736 (likely by selection) in other ORF's like ORF2 encoding Spike region.

737

738 **Figure 2. Accumulation of mutations in SARS-CoV-2 genomes and evolution of variants.**
739 **(A)** Dot plot representation of missense mutations identified in the SARS2-CoV-2 genome, of
740 which fourteen were found in the most abundant SNVs, including Threonine-to-Isoleucine (T>I)
741 and Proline-to-Leucine (P>L) change in ORF1b (present in about 48.79% and 80.2%) of the
742 sequences, respectively) and the well-documented Aspartic-acid-to-Glycine (D>G) change in
743 ORF2 (found in 80.76% of the sequences). A summary further detailing these predominant
744 mutations is provided in the Table 1 and Supplementary File 1. **(B)** Density histograms
745 (showing how the most common mutations from Fig 2A change over time), reveal that the most
746 common mutations can be grouped into four distinct patterns (A-D); these mutational co-
747 occurrences thus indicate the presence of at least three major variants. **(C)** Unique profiles of
748 co-occurring mutational signatures from the dataset were employed to compile 48 sub-variant
749 putative signatures (s1-s48; Figure S2A) distinct from the original Wuhan viral isolate (s0). 14
750 signatures and the s0, were found in more than 0.1% of the sequences. Time-scaled
751 phylogenetic tree of those 14 subvariants and s0 (highlighted in red) reveals accumulation of
752 mutations and more complex signatures with an acute burst of mutations in the summer of
753 2020 likely leading to a novel homegrown variant (s48). The first and last sequences by time
754 profiled (per signature) are denoted with light blue and red dots respectively. The reference

755 genome (Wuhan-Hu-1) is denoted with a dark purple dot. Gain of mutations in the clades is
756 denoted with red letters for each specific mutation, while loss with grey. The most abundant
757 signatures in the end of 2020 and early 2021 are s6, s22 and s48 (also shown in Figure S2B).
758

759 **Figure 3. SARS-CoV-2 viral isolate signatures change over time, but with different**
760 **patterns across states, showing dynamic evolution by mutation, drift and selection.**

761 Shown are state-specific ridgeline plots of the density of each signature (y axis) over collection
762 date (x axis). In each plot, peak colors gradually change to highlight transition in time (x axis),
763 with the pink-shaded areas corresponding to the periods of time where data was not available.
764 States shown were selected by sequence abundance throughout the year. Of note, the
765 reference strain s0 is virtually absent by June 2020, while signatures s6, s48, s22 are dominant
766 by late 2020.

767


768 **Figure 4. Variants of concern emerging in the United States include novel low frequency**
769 **mutations in key Spike protein functional domains. (A)** Sequence Alignment of the Spike

770 protein from 13 isolates in the overall US cohort, carrying the ΔH69/V70 previously described
771 deletion. Of note, three appear to be the B.1.1.7 variant containing the downstream deletion
772 (ΔV143/Y144)(38), first detected in the UK. Also shown are the consensus and reference
773 (NC_045512.2) sequences for the Spike protein. **(B)** Table summarizing further lineage
774 profiling of the 13 isolates shown in Fig 4A, collected from individuals after November 19th,
775 2020 (primarily in CA and FL). All isolates were either B.1.1.7 variants (3), or B.1.375 (10)
776 which lacked the ΔV143/Y144 deletion. Also of note, novel spike mutations were found in a
777 B.1.1.7 lineage isolate in FL (K1191N), as well as in two B.1.375 sequences (V758L and
778 C1236S in FL and CA, respectively). Dot entries in the last column denote the absence of
779 additional mutations. All mutations found in the Spike region of these isolates are summarized
780 in Supplementary Table 1. **(C)** Dot plots showing accumulation of multiple low frequency Spike
781 mutations (LFSM; >0.1% of cohort) in ORF2 over time. The amino acid position per LSFM is
782 shown at the bottom, while quartiles, from the first (Q1) till the last (Q4) are denoted on the

783 right. Mutations in Spike domains are further denoted by shaded areas; RBD/receptor binding
784 domain (red), FCS/furin cleavage site (green), FP/fusion peptide (orange), HR1/heptad repeat
785 region-1 (turquoise) and HR2/heptad repeat region-2 (violet).

786

787



788
789
790
791
792

Figure 1





Figure 2

793

794

795




796

797

Figure 3


A



B

Sequence ID	US State	Collection Date	Lineage	Additional Spike Mutations
MW430984.1	MA	2020-12-19	B.1.375	.
MW430977.1	FL	2020-12-20	B.1.375	.
MW430976.1	FL	2020-12-19	B.1.375	.
MW430975.1	FL	2020-12-20	B.1.375	.
MW430974.1	FL	2020-12-19	B.1.1.7	K1191N
MW430973.1	FL	2020-12-20	B.1.375	.
MW430972.1	FL	2020-12-19	B.1.375	V578L
MW430970.1	FL	2020-12-19	B.1.375	.
MW430966.1	CA	2020-12-20	B.1.1.7	.
MW430965.1	CA	2020-12-21	B.1.375	C1236S
MW430964.1	CA	2020-12-21	B.1.375	.
MW422255.1	CA	2020-12-12	B.1.1.7	.
MW406794.1	FL	2020-11-19	B.1.375	.

C



798

799

800

801

802

Figure 4

803 **SUPPORTING INFORMATION**

804 **S1 Figure. (A)** Viral sequences isolated from the United States from January 19th, 2020 till
805 January 6th, 2021 (8171 in total from SARS-CoV-2 NCBI portal; see *Methods*), highest
806 numbers were in mid- to late-March 2020. **(B)** States with the most sequences were WA, WI,
807 VA, CA, MA, FL, MN, MD, NY. Pie chart shows the percentage of sequences per state in from
808 the cohort in aggregate.

809

810 **S2 Figure. Associated information with Figures 2 and 3. (A)** Heatmap summarizing all the
811 putative signatures (columns) built by the unique combination of dominant mutations (rows).
812 Signatures are ranked from left to right by the sequence number they were found in (red labels
813 below x axis). The first 15 signatures that are found in 0.1% of the sequences (>8) or more
814 were considered for the mutational signature analysis. Presence or absence of mutation in
815 each signature is denoted with blue or light yellow respectively. **(B)** Signatures that were found
816 in more than 0.1% of the viral isolates in aggregate were further explored in the context of time
817 from emergence till early 2021. Viral isolates that were profiled with those signatures (s0, s1-
818 2, s6-8, s11-12, s22, s28, s34, s41-42, s48), were ordered by collection date in the columns of
819 the heatmap from left to right. The heatmap visualizes the % occurrence (light yellow to dark
820 blue scale) of each signature per collection date in the cohort of sequences. Column annotation
821 (bottom of the heatmap) denotes the different quartiles (Q1-Q4) of calendar year 2020 (very
822 few entries from Q1 of 2021 are shown) in which the sequences were collected. The non-
823 variant SARS-CoV-2 (s0) is present primarily in the in Q1 up to mid-Q2 of 2020. While a diverse
824 set of signatures appears in the USA from the start of the pandemic onward, subvariants
825 currently circulating in the American population are variations of s48, s22 and s6 (with some
826 variation per state).

827

828 **S1 Table.** Summarized information per viral isolate (rows) detected with deletion ΔH69/V70
829 alone or in combination with ΔV143/Y144. In the table, for each of the 13 isolates its NCBI
830 accession number as “Sequence ID” is given, along relevant information about the US State

831 or date that the isolate was collected. Dots (".") in the last column stand for silent mutations.
832 Mutations marked with bold red are novel ones for their lineage. Associated information with
833 Figures 4B-C.

834

835 **S1 File.** Robust list of mutations (silent and missense) detected in the cohort of sequences.

836

837 **S2 File.** Low Frequency Spike Mutations (LFSM) detected in the quartiles (Q1-4) of 2020.

838